Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review
Clinical Trial | By J Henzel, C Kępka, M Kruk et al.
OBJECTIVES - The authors sought to study the impact of diet and lifestyle intervention on changes in atherosclerotic plaque volume and composition. BACKGROUND - Lifestyle and diet modification are the leading strategies to manage coronary artery disease; however, their direct impact on atherosclerosis remains unknown. Coronary plaque composition is related to the risk of future cardiovascular events independen...
Pathophysiology, diagnosis and new therapeutic approaches for ischemic mitral regurgitation
Review Article | By S Hadjadj, O Marsit, J-M Paradis et al.
Ischemic mitral regurgitation is a valvular complication frequently seen in patients with coronary artery disease and associated with increased mortality and morbidity. Ischemic mitral regurgitation has a complex, heterogeneous and still incompletely understood pathophysiology involving both the mitral valve and the left ventricle. The occurrence of valve regurgitation in patients with ischemic cardiomyopathy will in return accelerate left ventricular rem...
Original Research | By K Vaidya , BJ Cochran, S Patel et al.
Review Article | By F Yarmohammadi, R Rezaee, AW Haye et al.
Doxorubicin (DOX) is a chemotherapeutic agent with marked, dose-dependent cardiotoxicity that leads to tachycardia, atrial and ventricular arrhythmia, and irreversible heart failure. Induction of the endoplasmic reticulum (ER) which plays a major role in protein folding and calcium homeostasis was reported as a key contributor to cardiac complications of DOX. This article reviews several chemical compounds that have been shown to regul...
Original Research | By WT Abraham, JA Lindenfeld, P Ponikowski et al.
AIMS - The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with p...
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
Clinical Trial | By J Brouwer, VJ Nijenhuis, R Delewi et al.
BACKGROUND - The effect of single as compared with dual antiplatelet treatment on bleeding and thromboembolic events after transcatheter aortic-valve implantation (TAVI) in patients who do not have an indication for long-term anticoagulation has not been well studied. METHODS - In a randomized, controlled trial, we assigned a subgroup of patients who were undergoing TAVI and did not have an indication fo...
Suture- or Plug-Based Large-Bore Arteriotomy Closure: A Pilot Randomized Controlled Trial
Clinical Trial | By MP van Wiechen, D Tchétché, N Dumonteil et al.
OBJECTIVES - The authors sought to test the superiority in terms of efficacy and safety of a dedicated plug-based vascular closure device (VCD) during transcatheter aortic valve replacement (TAVR) over a suture-based VCD. BACKGROUND - Vascular complications after TAVR are relevant and often associated with VCD failure. METHODS - The MASH trial (MANTA vs. Sut...
Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement
Original Research | By M Koschutnik, V Dannenberg, C Nitsche et al.
AIMS - Right ventricular dysfunction (RVD) on echocardiography has been shown to predict outcomes in patients undergoing transcatheter aortic valve replacement (TAVR). However, a comparison with the gold standard, RV ejection fraction (EF) on cardiovascular magnetic resonance (CMR), has never been performed. METHODS AND RESULTS - Consecutive patients scheduled for TAVR underwent echocardiogra...